(Q33359539)

26 July 2017

1 reference

title

Monoclonal antibodies in the treatment of autoimmune cytopenias (English)

1 reference

26 July 2017

1 reference

1 reference

1

Tadeusz Robak

1 reference

26 July 2017

publication date

1 February 2004

1 reference

European Journal of Haematology

26 July 2017

published in

1 reference

26 July 2017

volume

72

1 reference

26 July 2017

issue

2

1 reference

26 July 2017

page(s)

79-88

1 reference

CAMPATH-1H in the treatment of autoimmune cytopenias

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00196.X

Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00196.X

The effect of treatment with Campath-1H in patients with autoimmune cytopenias

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00196.X

Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00196.X

Rituximab for the treatment of refractory autoimmune hemolytic anemia in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00196.X

Monoclonal antibodies in the treatment of chronic lymphoid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00196.X

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00196.X

Sustained remission of platelet counts following monoclonal anti-CD20 antibody therapy in two cases of idiopathic autoimmune thrombocytopenia and neutropenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00196.X

Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00196.X

Successful treatment of a patient with hairy cell leukemia and pentostatin‐induced autoimmune thrombocytopenia with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00196.X

Treatment of childhood autoimmune haemolytic anaemia with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00196.X

Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00196.X

Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00196.X

Anti-CD20 monoclonal antibody therapy for autoimmune hemolytic anemia following T cell-depleted, haplo-identical stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00196.X

Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00196.X

Beneficial effects of rituximab on primary cold agglutinin disease refractory to conventional therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00196.X

Mixed warm and cold autoimmune hemolytic anemia: complete recovery after 2 courses of rituximab treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00196.X

Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00196.X

Successful treatment of pure red cell aplasia with a single dose of rituximab in a child after major ABO incompatible peripheral blood allogeneic stem cell transplantation for acquired aplastic anemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00196.X

Restoration of erythropoiesis by rituximab in an adult patient with primary acquired pure red cell aplasia refractory to conventional treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00196.X

Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00196.X

Multiple complications of IVIG therapy in a patient with Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00196.X

Treatment of refractory autoimmune haemolytic anaemia with anti-CD20 (rituximab)

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00196.X

Sustained response of refractory chronic lymphocytic leukemia in progression complicated by acute hemolitic anemia to anti-CD20 monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00196.X

Rituximab in lymphoma with life threatening haemolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00196.X

Rituximab for immune hemolytic anemia following T- and B-Cell-depleted hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00196.X

Successful treatment of refractory autoimmune haemolytic anaemia in a post-unrelated bone marrow transplant paediatric patient with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00196.X

Childhood refractory autoimmune haemolytic anaemia: is there a role for anti-CD20 therapy (rituximab)?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00196.X

Rituximab in a case of cold agglutinin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00196.X

Remission of severe cold agglutinin disease after Rituximab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00196.X

Rituximab: a very efficient therapy in cold agglutinins and refractory autoimmune haemolytic anaemia associated with CD20-positive, low-grade non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00196.X

[Rituximab in cold agglutinin disease]

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00196.X

Severe cold hemagglutinin disease (CHD) successfully treated with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00196.X

Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00196.X

Successful response to rituximab in a patient with pure red cell aplasia complicating chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0902-4441.2003.00196.X

10.1046/J.0902-4441.2003.00196.X

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference